Twist Bioscience (NASDAQ:TWST) CEO Sells $14,182,880.88 in Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 113,318 shares of the firm’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the sale, the chief executive officer directly owned 818,938 shares in the company, valued at approximately $102,498,280.08. This represents a 12.16% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Price Performance

Shares of TWST opened at $118.57 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 2.38 and a current ratio of 2.67. The stock has a 50 day simple moving average of $94.56 and a 200 day simple moving average of $67.15. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $126.40. The firm has a market capitalization of $7.44 billion, a PE ratio of -53.41 and a beta of 2.14.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.The company had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. During the same quarter last year, the business posted $0.33 earnings per share. The business’s quarterly revenue was up 23.2% on a year-over-year basis. Sell-side analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

TWST has been the topic of several research reports. Barclays boosted their price objective on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday, June 24th. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday, June 24th. Canaccord Genuity Group increased their price objective on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Robert W. Baird lifted their target price on Twist Bioscience from $113.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, August 4th. Finally, Piper Sandler upped their price target on Twist Bioscience from $85.00 to $115.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.30.

Hedge Funds Weigh In On Twist Bioscience

Several hedge funds have recently modified their holdings of the stock. Quarry LP bought a new stake in Twist Bioscience during the third quarter worth about $28,000. Western Wealth Management LLC acquired a new position in shares of Twist Bioscience during the 1st quarter worth approximately $31,000. Strs Ohio acquired a new position in shares of Twist Bioscience during the 1st quarter worth approximately $33,000. Strategic Advocates LLC raised its stake in shares of Twist Bioscience by 562.7% during the 4th quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after purchasing an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. raised its stake in shares of Twist Bioscience by 68.9% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock worth $44,000 after purchasing an additional 571 shares in the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.